Red Flags Detected

• ⚠ Going Concern (new) — Company disclosed substantial doubt about ability to continue operating due to recurring losses, negative cash flows, and working capital deficit.
• ⚠ Material Weakness (new) — Company disclosed material weaknesses in internal controls including inadequate policies, documentation, system access, and segregation of duties.
• ⚠ Asset Impairment (new) — Company recorded $2.6 million impairment on intellectual property related to discontinued colorectal cancer product lines.
• ⚠ Related Party (new) — Company sold its European Oncology Lab business to a related party as part of restructuring efforts.